By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Novozymes A/S et al. v. Central Trading Enterprises, Inc.
1:11-cv-04276; filed June 23, 2011 in the Northern District of Illinois
• Plaintiffs: Novozymes A/S; Novozymes North America, Inc.
• Defendant: Central Trading Enterprises, Inc.
Infringement of U.S. Patent Nos. 6,255,084 ("Thermostable Glucoamylase," issued July 3, 2001) and 7,060,468 (same title, issued June 13, 2006) based on CTE's manufacture and sale of its GLUCOAMYL L 706+ and GLUCOAMYL LG20 products. View the complaint here.
Teva Neuroscience, Inc. et al. v. Apotex Inc. et al.
0:11-cv-61402; filed June 22, 2011 in the Southern District of Florida
• Plaintiffs: Teva Neuroscience, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.
• Defendants: Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. 5,453,446 ("Use of the R-Enantiomers of N-Propargyl 1-Aminoindan Compounds for Treating Parkinson's Disease," issued September 26, 1995) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Teva's Azilect® (rasagiline mesylate, used to treat idiopathic Parkinson's disease). View the complaint here.
Astellas US LLC et al. v. Sagent Pharmaceuticals, Inc. et al.
3:11-cv-03533; filed June 20, 2011 in the District Court of New Jersey
• Plaintiffs: Astellas US LLC; Astellas Pharma US, Inc.; Item Development AB
• Defendants: Sagent Pharmaceuticals, Inc.; Strides Arcolab Ltd.; Strides Inc.; Sagent Strides LLC
Infringement of U.S. Patent No. 5,731,296 ("Selective Vasodilation by Continuous Adenosine Infusion," issued March 24, 1998), licensed to Astellas, following a Paragraph IV certification as part of Sagent's filing of an ANDA to manufacture a generic version of Astellas' Adenoscan® product (adenosine injection, used as a diagnostic for myocardial reperfusion injury). View the complaint here.
Depomed, Inc. et al. v. Sun Pharma Global FZE et al.
3:11-cv-03553; filed June 20, 2011 in the District Court of New Jersey
• Plaintiffs: Depomed, Inc.; Valeant International (Barbados) SRL
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Inc.
Infringement of U.S. Patent Nos. 6,723,340 ("Optimal Polymer Mixtures for Gastric Retentive Tablets," issued April 20, 2004), 6,635,280 ("Extending the Duration of Drug Release Within the Stomach During the Fed Mode," issued October 21, 2003), 6,488,962 ("Tablet Shapes to Enhance Gastric Retention of Swellable Controlled-Release Oral Dosage Forms, issued December 3, 2002), 6,340,475 ("Extending the Duration of Drug Release Within the Stomach During the Fed Mode," issued January 22, 2002), 7,736,667 ("Shell-and-Core Dosage Form Approaching Zero-Order Drug Release," issued June 15, 2010), 7,780,987 ("Controlled Release Dosage Forms," issued August 24, 2010) following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Depomed's Glumetza® (metformin hydrochloride extended release tablets, used to improve glycemic control in adults with type 2 diabetes mellitus). View the complaint here.
GlaxoSmithKline LLC v. Roxane Laboratories Inc. et al.
1:11-cv-00542; filed June 17, 2011 in the District Court of Delaware
• Plaintiff: GlaxoSmithKline LLC
• Defendants: Roxane Laboratories Inc.; Watson Pharma Inc.; Watson Pharmaceuticals Inc.; Watson Laboratories Inc. - Florida
Infringement of U.S. Patent Nos. 5,565,467 ("Androstenone Derivative," issued October 15, 1996), 5,846,976 (same title, issued December 8, 1998), and 5,998,427 ("Androstenones," issued December 7, 1999) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of GSK's Avodart® (dutasteride, used to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate). View the complaint here.
Sanofi-Aventis U.S. LLC et al. v. Sun Pharma Global FZE et al.
3:11-cv-03532; filed June 17, 2011 in the District Court of New Jersey
• Plaintiffs: Sanofi-Aventis U.S. LLC; Sanofi-Aventis; Debiopharm S.A.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries, Inc.; Sun Pharmaceutical Industries Ltd.; Caraco Pharmaceutical Laboratories, Ltd.
Infringement of U.S. Patent Nos. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994), 5,716,988 ("Pharmaceutically Stable Preparation of Oxaliplatinum," issued February 10, 1998), and 5,959,133 ("Process for the Preparation of Platinum Compounds," issued September 28, 1999) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.
Comments